Sanofi is cooperating with ShangPharma to promote three vaccine products in some large markets.

As learned from Sanofi, starting from January 1, 2026, Sanofi will utilize the strength of its local partner Shangyao Pharmaceutical Park's wholly-owned subsidiary Hongyao Technology to provide academic promotion services for the vaccination points of the three vaccine products, Pan Tai Xin, Fenjie and Fanerling, in some vast market areas, further enhancing accessibility. Sanofi will continue to be responsible for the import, distribution, and academic promotion work of the three products nationwide.